FDA grants Fast Track designation to MS drug
Posted: Tue Mar 22, 2016 5:53 am
MediciNova, Inc says it has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the development of MN-166 (ibudilast) for the treatment of patients with progressive multiple sclerosis (progressive MS)...Read more - http://www.ms-uk.org/MSnews